Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Income towards Parent Company: 2017-2024

Historic Income towards Parent Company for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to -$543.3 million.

  • BridgeBio Pharma's Income towards Parent Company fell 12.59% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$763.1 million, marking a year-over-year decrease of 85.40%. This contributed to the annual value of -$543.3 million for FY2024, which is 16.82% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Income towards Parent Company is -$543.3 million, which was up 16.82% from -$653.3 million recorded in FY2023.
  • BridgeBio Pharma's 5-year Income towards Parent Company high stood at -$485.1 million for FY2022, and its period low was -$653.3 million during FY2023.
  • In the last 3 years, BridgeBio Pharma's Income towards Parent Company had a median value of -$543.3 million in 2024 and averaged -$560.6 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Income towards Parent Company crashed by 75.16% in 2020, and later climbed by 17.29% in 2022.
  • BridgeBio Pharma's Income towards Parent Company (Yearly) stood at -$505.5 million in 2020, then declined by 16.02% to -$586.5 million in 2021, then rose by 17.29% to -$485.1 million in 2022, then slumped by 34.67% to -$653.3 million in 2023, then grew by 16.82% to -$543.3 million in 2024.